Skip to main content
Erschienen in: International Urogynecology Journal 8/2011

01.08.2011 | Original Article

Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire

verfasst von: Linda Brubaker, Vik Khullar, Elisabeth Piault, Christopher J. Evans, Tamara Bavendam, James Beach, Yating Yeh, Zoe S. Kopp, Con J. Kelleher, Jeffrey Trocio

Erschienen in: International Urogynecology Journal | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

The Self-Assessment Goal Achievement (SAGA) questionnaire was developed to identify treatment goals and assess goal-achievement in patients with lower urinary tract symptoms (LUTS).

Methods

This study consisted of (1) gathering information on goal setting/attainment concepts, (2) goal elicitation (n = 41 patients with LUTS), (3) cognitive debriefing of draft questionnaire (n = 11), and (4) pilot testing (n = 104).

Results

SAGA consists of baseline (goal-assessment; ranking) and follow-up (goal-achievement) modules. In addition to goals most frequently mentioned, patients can list up to five open goals. Goals most commonly reported as “very important” in pilot testing included reducing urgency (72%), incontinence (65%), and nocturia (64%). Treatment goals spontaneously reported as “very important” were reducing incontinence (45%), nocturia (40%), and frequency (26%).

Conclusions

SAGA may be used to identify treatment goals and assess goal-achievement in patients with LUTS in the clinic and for research (with additional validation). This information may promote patient–physician interaction and help patients establish realistic treatment goals, which may in turn improve treatment adherence and outcomes.
Literatur
1.
Zurück zum Zitat Brubaker L, Chapple C, Coyne KS, Kopp Z (2006) Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 68:3–8PubMedCrossRef Brubaker L, Chapple C, Coyne KS, Kopp Z (2006) Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 68:3–8PubMedCrossRef
2.
Zurück zum Zitat Elkadry EA, Kenton KS, FitzGerald MP, Shott S, Brubaker L (2003) Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 189:1551–1557PubMedCrossRef Elkadry EA, Kenton KS, FitzGerald MP, Shott S, Brubaker L (2003) Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 189:1551–1557PubMedCrossRef
3.
Zurück zum Zitat Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276–1282PubMedCrossRef Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276–1282PubMedCrossRef
4.
Zurück zum Zitat Marschall-Kehrel D, Roberts RG, Brubaker L (2006) Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 68(suppl 2A):29–37PubMedCrossRef Marschall-Kehrel D, Roberts RG, Brubaker L (2006) Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 68(suppl 2A):29–37PubMedCrossRef
5.
Zurück zum Zitat Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K (2008) Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 101:1381–1387PubMedCrossRef Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K (2008) Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 101:1381–1387PubMedCrossRef
6.
Zurück zum Zitat Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R (2006) Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60:745–751PubMedCrossRef Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R (2006) Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60:745–751PubMedCrossRef
7.
Zurück zum Zitat Rosenberg MT (2006) Overactive bladder made ridiculously simple? Int J Clin Pract 60:631–634PubMedCrossRef Rosenberg MT (2006) Overactive bladder made ridiculously simple? Int J Clin Pract 60:631–634PubMedCrossRef
8.
Zurück zum Zitat Khan MS, Chaliha C, Leskova L, Khullar V (2005) A randomized crossover trial to examine administration techniques related to the Bristol female lower urinary tract symptom (BFLUTS) questionnaire. Neurourol Urodyn 24:211–214PubMedCrossRef Khan MS, Chaliha C, Leskova L, Khullar V (2005) A randomized crossover trial to examine administration techniques related to the Bristol female lower urinary tract symptom (BFLUTS) questionnaire. Neurourol Urodyn 24:211–214PubMedCrossRef
9.
Zurück zum Zitat MacDiarmid S, Rosenberg M (2005) Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 21:1413–1421PubMedCrossRef MacDiarmid S, Rosenberg M (2005) Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 21:1413–1421PubMedCrossRef
10.
Zurück zum Zitat Nicolson P, Kopp Z, Chapple CR, Kelleher C (2008) It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol 13:343–359PubMedCrossRef Nicolson P, Kopp Z, Chapple CR, Kelleher C (2008) It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol 13:343–359PubMedCrossRef
11.
Zurück zum Zitat Sung VW, Raker CA, Myers DL, Clark MA (2010) Treatment decision-making and information-seeking preferences in women with pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 21:1071–1078CrossRef Sung VW, Raker CA, Myers DL, Clark MA (2010) Treatment decision-making and information-seeking preferences in women with pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 21:1071–1078CrossRef
12.
Zurück zum Zitat Kiresuk TJ, Lund SH, Larsen NE (1982) Measurement of goal attainment in clinical and health care programs. Drug Intell Clin Pharm 16:145–153PubMed Kiresuk TJ, Lund SH, Larsen NE (1982) Measurement of goal attainment in clinical and health care programs. Drug Intell Clin Pharm 16:145–153PubMed
13.
Zurück zum Zitat Ashford S, Turner-Stokes L (2006) Goal attainment for spasticity management using botulinum toxin. Physiother Res Int 11:24–34PubMedCrossRef Ashford S, Turner-Stokes L (2006) Goal attainment for spasticity management using botulinum toxin. Physiother Res Int 11:24–34PubMedCrossRef
14.
Zurück zum Zitat Hullfish KL, Bovbjerg VE, Gibson J, Steers WD (2002) Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol 187:88–92PubMedCrossRef Hullfish KL, Bovbjerg VE, Gibson J, Steers WD (2002) Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol 187:88–92PubMedCrossRef
15.
Zurück zum Zitat Brubaker L, Kopp Z, Piault E, Trocio J, Evans C, Fitzgerald K, et al (2007) Development of a Self-Assessment Goal Achievement (SAGA) questionnaire in urinary disorders. Paper presented at International Continence Society, Rotterdam, The Netherlands, August 20–24, 2007 Brubaker L, Kopp Z, Piault E, Trocio J, Evans C, Fitzgerald K, et al (2007) Development of a Self-Assessment Goal Achievement (SAGA) questionnaire in urinary disorders. Paper presented at International Continence Society, Rotterdam, The Netherlands, August 20–24, 2007
16.
Zurück zum Zitat Fianu-Jonasson A, Brubaker L, Kelleher C, Khullar V, Bitoun CE, Weinstein D, et al (2009) Understanding Swedish patients’ expectations for treatment of their urinary symptoms. Paper presented at Nordic Urogynecological Association, Reykjavik, Iceland, May 14–16, 2009 Fianu-Jonasson A, Brubaker L, Kelleher C, Khullar V, Bitoun CE, Weinstein D, et al (2009) Understanding Swedish patients’ expectations for treatment of their urinary symptoms. Paper presented at Nordic Urogynecological Association, Reykjavik, Iceland, May 14–16, 2009
17.
Zurück zum Zitat Mahajan ST, Elkadry EA, Kenton KS, Shott S, Brubaker L (2006) Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 194:722–728PubMedCrossRef Mahajan ST, Elkadry EA, Kenton KS, Shott S, Brubaker L (2006) Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 194:722–728PubMedCrossRef
18.
Zurück zum Zitat Payne C, Allee T (2009) Goal achievement provides new insights into interstitial cystitis/painful bladder syndrome symptoms and outcomes. Neurourol Urodyn 28:13–17PubMedCrossRef Payne C, Allee T (2009) Goal achievement provides new insights into interstitial cystitis/painful bladder syndrome symptoms and outcomes. Neurourol Urodyn 28:13–17PubMedCrossRef
19.
Zurück zum Zitat Milne JL, Robert M, Tang S, Drummond N, Ross S (2009) Goal achievement as a patient-generated outcome measure for stress urinary incontinence. Health Expect 12:288–300PubMedCrossRef Milne JL, Robert M, Tang S, Drummond N, Ross S (2009) Goal achievement as a patient-generated outcome measure for stress urinary incontinence. Health Expect 12:288–300PubMedCrossRef
20.
Zurück zum Zitat Lowenstein L, FitzGerald MP, Kenton K, Dooley Y, Templehof M, Mueller ER et al (2008) Patient-selected goals: the fourth dimension in assessment of pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 19:81–84PubMed Lowenstein L, FitzGerald MP, Kenton K, Dooley Y, Templehof M, Mueller ER et al (2008) Patient-selected goals: the fourth dimension in assessment of pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 19:81–84PubMed
21.
Zurück zum Zitat US Department of Health and Human Services (2009) Patient-reported outcome measures: use in medical product development to support labeling claims. Health Qual Life Outcomes 4:79 US Department of Health and Human Services (2009) Patient-reported outcome measures: use in medical product development to support labeling claims. Health Qual Life Outcomes 4:79
22.
Zurück zum Zitat Charmaz K (1995) Grounded theory. In: Smith JA, Harre R, Van Langenhove L (eds) Rethinking methods in psychology. Sage, London, pp 27–49 Charmaz K (1995) Grounded theory. In: Smith JA, Harre R, Van Langenhove L (eds) Rethinking methods in psychology. Sage, London, pp 27–49
23.
Zurück zum Zitat Strauss A, Corbin J (1998) Basics of qualitative research: Techniques and procedures for developing grounded theory. Sage, London Strauss A, Corbin J (1998) Basics of qualitative research: Techniques and procedures for developing grounded theory. Sage, London
24.
Zurück zum Zitat Charmaz K (1991) Good days, bad days: The self in chronic illness and time. Rutgers University Press, New Brunswick Charmaz K (1991) Good days, bad days: The self in chronic illness and time. Rutgers University Press, New Brunswick
25.
Zurück zum Zitat Glaser B, Strauss AL (1967) The constant comparative methods of qualitative analysis. In: Discovery of grounded theory. Aldine de Gruyter, New York, p 101 Glaser B, Strauss AL (1967) The constant comparative methods of qualitative analysis. In: Discovery of grounded theory. Aldine de Gruyter, New York, p 101
26.
Zurück zum Zitat Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574PubMedCrossRef
27.
Zurück zum Zitat Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P (2008) Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 27:179–190PubMedCrossRef Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P (2008) Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 27:179–190PubMedCrossRef
28.
Zurück zum Zitat Krueger KP, Berger BA, Felkey B (2005) Medication adherence and persistence: a comprehensive review. Adv Ther 22:313–356PubMedCrossRef Krueger KP, Berger BA, Felkey B (2005) Medication adherence and persistence: a comprehensive review. Adv Ther 22:313–356PubMedCrossRef
29.
Zurück zum Zitat Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129PubMed Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129PubMed
30.
Zurück zum Zitat Rockwood K, Stolee P, Fox RA (1993) Use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol 46:1113–1118PubMedCrossRef Rockwood K, Stolee P, Fox RA (1993) Use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol 46:1113–1118PubMedCrossRef
Metadaten
Titel
Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire
verfasst von
Linda Brubaker
Vik Khullar
Elisabeth Piault
Christopher J. Evans
Tamara Bavendam
James Beach
Yating Yeh
Zoe S. Kopp
Con J. Kelleher
Jeffrey Trocio
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 8/2011
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-011-1382-7

Weitere Artikel der Ausgabe 8/2011

International Urogynecology Journal 8/2011 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.